Close Menu

Breaking News

Qiagen can now sell Phase's proprietary proximity-ligation technology for chromatin conformational analysis research in the US.

News items for the week of Oct. 26, 2020. 

Oxsed, a University of Oxford spinout, will continue to focus on prioritizing test access for low- and middle-income countries following the acquisition.

The point-of-care test runs on the VitaPCR instrument and delivers results in 20 minutes, and has been implemented at Charles De Gaulle airport.

The reissued EUA is for the qualitative detection of nucleic acid from SARS-CoV-2 in human oropharyngeal swab, nasopharyngeal swab, and anterior nasal swab specimens.

The firm's subsidiary BioReference Laboratories performed 3.5 million COVID-19 PCR tests and 300,000 serology tests during the quarter.

Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.

The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.

Illumina reported total third quarter revenues of $794 million. On the investor conference call, Illumina's CEO justified the $8 billion Grail deal.

The firm reported $57.8 million in revenues for its Lyra SARS-CoV-2 molecular diagnostic assays in the quarter.

The genetic population structures of dogs and humans broadly resemble one another, suggesting that as people migrated, so did dogs.

As a result of the expanded coverage, Natera said it believes there are currently 139 million people covered in the US for average risk NIPT.

Max Planck Institute for Evolutionary Anthropology researchers sequenced the nuclear genome isolated from 34,000-year-old skull bone uncovered in eastern Mongolia.

Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.

SomaLogic and the FDA will use the company's SomaScan proteomics platform to identify circulating pharmacodynamic biomarkers for biologics.

The CRISPR-based test uses Mammoth's DETECTR BOOST platform and will be compatible with both nasal swab and saliva samples.

Researchers combined protein expression with mutational analysis to map the somatic genotype and clonal architecture of AML with its immunophenotype.

The companies said their partnership will allow pharmaceutical partners to measure both ctDNA and CTC biomarkers from a single blood draw when conducting drug trials.

Results of three studies, which had overlapping findings, were presented at the American Society of Human Genetics 2020 virtual meeting on Wednesday.

The firms had planned to develop the assay on Biocartis' Idylla platform, which would have allowed customers to perform the assay locally in their own lab facilities.

Inivata's Radar assay will be used to monitor circulating tumor DNA from multiple tumor types in trial participants following treatment with Maverick's MVC-101 candidate. 

The firm said it made changes to address the pandemic that allowed it to submit its Parsortix cell-sorting system to the FDA for use in metastatic breast cancer.

The funding is part of a BARDA contract worth up to $72 million to support the development of a test to diagnose acute infection at the point of care.

Pages

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.